NUVILEX INC (NVLX)

0.14

0.00 0.69

OTC

Jun 1, 2015 3:58 PM EDT

Prev Close	0.14
Open	0.14
Day Low/High	0.14 / 0.15
52 Wk Low/High	0.10 / 0.33
Volume	3.32M

Exchange	OTC
Shares Outstanding	699.29M
Market Cap	136.36M
Div & Yield	N.A. (N.A)

Latest News

Nuvilex Announces Name Change To PharmaCyte Biotech

Nuvilex To Attend 2015 Gastrointestinal Cancers Symposium In San Francisco, January 15-17, 2015

Nuvilex Announces Name Change To PharmaCyte Biotech

Company's Shares Will Trade Under New Ticker Symbol PHCB

GlobeNewswire

Jan 7, 2015 9:30 AM EST

Nuvilex To Attend 2015 Gastrointestinal Cancers Symposium In San Francisco, January 15-17, 2015

GlobeNewswire

Jan 6, 2015 9:30 AM EST

FDA Grants Orphan Drug Designation To Nuvilex For Pancreatic Cancer Treatment

GlobeNewswire

Dec 22, 2014 8:30 AM EST

Nuvilex's Partner Austrianova Successfully Completes First Live Cell Encapsulation In New Facility

GlobeNewswire

Dec 18, 2014 9:30 AM EST

Nuvilex Provides Shareholder Update On Cancer And Diabetes Programs

GlobeNewswire

Dec 16, 2014 9:30 AM EST

Nuvilex Provides Update On Significance Of Austrianova's CGMP Live-Cell Encapsulation Facility

GlobeNewswire

Dec 10, 2014 9:30 AM EST

Nuvilex Announces Name Change Of Subsidiary To Viridis Biotech

GlobeNewswire

Dec 8, 2014 9:30 AM EST

Nuvilex Announces The Opening Of Austrianova's CGMP Live Cell Encapsulation Facility In Thailand

GlobeNewswire

Dec 4, 2014 9:30 AM EST

Nuvilex Obtains Exclusive Worldwide License To Develop Disease Treatments That Combine Cell-in-a-Box(R) And Cannabinoid-Based Medicine

GlobeNewswire

Dec 1, 2014 9:30 AM EST

Nuvilex Executives In Southeast Asia To Further Advance Cell-in-a-Box Technology(R)

GlobeNewswire

Nov 21, 2014 9:36 AM EST

Nuvilex Announces Preliminary Data From Preclinical Study Of Effects Of Its Pancreatic Cancer Treatment On Ascites Fluid Formation

GlobeNewswire

Nov 19, 2014 9:30 AM EST

Nuvilex Applies In Australia For The Orphan Drug Designation For Pancreatic Cancer Treatment

GlobeNewswire

Nov 7, 2014 9:30 AM EST

Nuvilex Contracts With University Of Veterinary Medicine In Vienna To Conduct Preclinical Studies On The Use Of Cell-in-a Box(R) To Develop Diabetes Treatment

GlobeNewswire

Oct 20, 2014 9:00 AM EDT

Nuvilex Secures Worldwide License For Insulin-Producing Cells From University Of Technology, Sydney, For Use In Developing Diabetes Treatment

GlobeNewswire

Oct 16, 2014 9:00 AM EDT

Nuvilex Applies To FDA For Orphan Drug Designation For Its Cell-in-a-Box(R) Treatment For Pancreatic Cancer

GlobeNewswire

Oct 13, 2014 9:00 AM EDT

Nuvilex Appoints Dr. Matthias Lohr As Chairman Of Scientific Advisory Board

GlobeNewswire

Oct 6, 2014 9:00 AM EDT

Nuvilex Announces Strategic Changes To Leadership Team And Appoints Prof. Dr. Walter H. Gunzburg As Chief Scientific Officer

GlobeNewswire

Oct 1, 2014 9:00 AM EDT

Nuvilex's Partner, Austrianova, Publishes Scientific Review Article Emphasizing Use Of Cell-in-a-Box(R) For Treatment Of Diabetes

GlobeNewswire

Sep 22, 2014 9:00 AM EDT

Nuvilex Updates Shareholders On Recent Activities And Discusses Future Plans For Development Of Treatments For Cancer And Diabetes

GlobeNewswire

Sep 18, 2014 10:49 AM EDT

Nuvilex Updates Shareholders On Recent Activities And Discusses Future Plans For Development Of Treatments For Cancer And Diabetes

GlobeNewswire

Sep 18, 2014 9:24 AM EDT

Nuvilex's Partner, Austrianova, Receives Prestigious Emerging Enterprises 2014 Best Innovation Award In Singapore

GlobeNewswire

Sep 5, 2014 1:22 PM EDT

Nuvilex Submits Application For Orphan Drug Designation To The European Medicines Agency For Its Cell-in-a-Box(R) Treatment For Pancreatic Cancer

GlobeNewswire

Sep 2, 2014 9:00 AM EDT

Nuvilex Begins Preclinical Studies With Translational Drug Development To Determine If Nuvilex's Unique Cancer Treatment Can Slow Accumulation Of Malignant Ascites Fluid

GlobeNewswire

Aug 20, 2014 9:00 AM EDT

Nuvilex Announces Publication Of Combined Results Of The Initial Phase 1/2 Clinical Trial And A Second Phase 2 Clinical Trial Of The Cell-in-a-Box(R) Plus Ifosfamide Combination In Patients With Advanced, Inoperable Pancreatic Cancer

GlobeNewswire

Aug 14, 2014 9:00 AM EDT

Nuvilex Provides Update On Status Of Preclinical Studies At Translational Drug Development

GlobeNewswire

Aug 13, 2014 9:00 AM EDT

Nuvilex Announces That Dr. Richard M. Hyslop Will Present At The ACS Annual Meeting On "Sustainable, Green Chemistry And Medicine: Targeted Cannabinoid-Based Chemotherapy Utilizing Cell-in-a-Box(R) Live Cell Encapsulation Technology."

GlobeNewswire

Aug 4, 2014 9:45 AM EDT

Nuvilex And Austrianova Announce Results Of Clinical Trial In Dogs With Mammary Tumors Treated With Cell-in-a-Box(R) Plus Cyclophosphamide

GlobeNewswire

Jul 17, 2014 9:00 AM EDT

Nuvilex Provides Shareholder Update On Milestone Accomplishments

GlobeNewswire

Jul 14, 2014 9:00 AM EDT

Nuvilex Scheduled To Begin Preclinical Studies In Early August

Preparations for Preclinical Studies on the Effect of Nuvilex's Pancreatic Cancer Treatment on Ascites Fluid Accumulation Completed

GlobeNewswire

Jul 9, 2014 9:00 AM EDT

Nuvilex Executives Attend 2014 BIO International Convention

Meet With Global Development Partners

GlobeNewswire

Jul 1, 2014 9:00 AM EDT

NUVILEX INC (NVLX)

Latest News

Nuvilex Announces Name Change To PharmaCyte Biotech

Nuvilex To Attend 2015 Gastrointestinal Cancers Symposium In San Francisco, January 15-17, 2015

Nuvilex Announces Name Change To PharmaCyte Biotech

Nuvilex To Attend 2015 Gastrointestinal Cancers Symposium In San Francisco, January 15-17, 2015

FDA Grants Orphan Drug Designation To Nuvilex For Pancreatic Cancer Treatment

Nuvilex's Partner Austrianova Successfully Completes First Live Cell Encapsulation In New Facility

Nuvilex Provides Shareholder Update On Cancer And Diabetes Programs

Nuvilex Provides Update On Significance Of Austrianova's CGMP Live-Cell Encapsulation Facility

Nuvilex Announces Name Change Of Subsidiary To Viridis Biotech

Nuvilex Announces The Opening Of Austrianova's CGMP Live Cell Encapsulation Facility In Thailand

Nuvilex Obtains Exclusive Worldwide License To Develop Disease Treatments That Combine Cell-in-a-Box(R) And Cannabinoid-Based Medicine

Nuvilex Executives In Southeast Asia To Further Advance Cell-in-a-Box Technology(R)

Nuvilex Announces Preliminary Data From Preclinical Study Of Effects Of Its Pancreatic Cancer Treatment On Ascites Fluid Formation

Nuvilex Applies In Australia For The Orphan Drug Designation For Pancreatic Cancer Treatment

Nuvilex Contracts With University Of Veterinary Medicine In Vienna To Conduct Preclinical Studies On The Use Of Cell-in-a Box(R) To Develop Diabetes Treatment

Nuvilex Secures Worldwide License For Insulin-Producing Cells From University Of Technology, Sydney, For Use In Developing Diabetes Treatment

Nuvilex Applies To FDA For Orphan Drug Designation For Its Cell-in-a-Box(R) Treatment For Pancreatic Cancer

Nuvilex Appoints Dr. Matthias Lohr As Chairman Of Scientific Advisory Board

Nuvilex Announces Strategic Changes To Leadership Team And Appoints Prof. Dr. Walter H. Gunzburg As Chief Scientific Officer

Nuvilex's Partner, Austrianova, Publishes Scientific Review Article Emphasizing Use Of Cell-in-a-Box(R) For Treatment Of Diabetes

Nuvilex Updates Shareholders On Recent Activities And Discusses Future Plans For Development Of Treatments For Cancer And Diabetes

Nuvilex Updates Shareholders On Recent Activities And Discusses Future Plans For Development Of Treatments For Cancer And Diabetes

Nuvilex's Partner, Austrianova, Receives Prestigious Emerging Enterprises 2014 Best Innovation Award In Singapore

Nuvilex Submits Application For Orphan Drug Designation To The European Medicines Agency For Its Cell-in-a-Box(R) Treatment For Pancreatic Cancer

Nuvilex Begins Preclinical Studies With Translational Drug Development To Determine If Nuvilex's Unique Cancer Treatment Can Slow Accumulation Of Malignant Ascites Fluid

Nuvilex Announces Publication Of Combined Results Of The Initial Phase 1/2 Clinical Trial And A Second Phase 2 Clinical Trial Of The Cell-in-a-Box(R) Plus Ifosfamide Combination In Patients With Advanced, Inoperable Pancreatic Cancer

Nuvilex Provides Update On Status Of Preclinical Studies At Translational Drug Development

Nuvilex Announces That Dr. Richard M. Hyslop Will Present At The ACS Annual Meeting On "Sustainable, Green Chemistry And Medicine: Targeted Cannabinoid-Based Chemotherapy Utilizing Cell-in-a-Box(R) Live Cell Encapsulation Technology."

Nuvilex And Austrianova Announce Results Of Clinical Trial In Dogs With Mammary Tumors Treated With Cell-in-a-Box(R) Plus Cyclophosphamide

Nuvilex Provides Shareholder Update On Milestone Accomplishments

Nuvilex Scheduled To Begin Preclinical Studies In Early August

Nuvilex Executives Attend 2014 BIO International Convention

Trending

Advertising Partners